A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

This will be a multi-center, global, open-label study in adult suffering from fluctuating
Parkinson's disease subjects who have successfully completed the core study IN 11 004.

After signing informed consent and meeting inclusion/exclusion criteria, eligible subjects
will be enrolled into a 12-month open-label extension and receive the AP-CD/LD as needed.

Efficacy and safety will be assessed throughout the study period.

Inclusion Criteria:

1. Subjects who successfully completed the core study IN 11 004 and, in the opinion of
the Investigator, would benefit from long-term treatment with AP-CD/LD

2. Continue to carry the diagnosis of Parkinson's disease consistent with UK brain bank
criteria

3. Has a good response to Levodopa in the opinion of the investigator

4. Subjects able and willing to give written (signed and dated) informed consent to
participate in the study

Exclusion Criteria:

1. Participation in another clinical trial other than IN 11 004 and receipt of an
investigational medication other than that administered in the context of IN 11 004
within 28 days prior to the planned start of treatment

2. Previous or planned neurosurgical or Duodopa treatment for Parkinson's Disease (e.g.,
procedures including ablation or deep brain stimulation)

3. Non-selective monoamine oxidase (MAO) inhibitors within 28 days prior to Baseline
Visit or planned administration during study participation

4. If, in the opinion of the Investigator, subject should not participate in the study

5. Women who are pregnant or nursing. Women of childbearing potential who are not willing
to use a medically acceptable method of contraception.